INFLECTIS BIOSCIENCE
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- -
Treatment Combining Riluzole and IFB-088 in Bulbar Amyotrophic Lateral Sclerosis (TRIALS Protocol)
Phase 2
Active, not recruiting
- Conditions
- Amyotrophic Lateral SclerosisALS
- Interventions
- First Posted Date
- 2022-08-19
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- InFlectis BioScience
- Target Recruit Count
- 51
- Registration Number
- NCT05508074
- Locations
- 🇫🇷
CHU de Nice Pasteur 2-zone C, NICE Cedex 1, France
🇫🇷APHM Hôpital La Timone Adultes SCE Maladies Neuromusculaires / SLA, Marseille Cedex 05, France
🇫🇷CHU de Toulouse - Hôpital Pierre-Paul Riquet, Toulouse Cedex 9, France
A Combined SAD and MAD Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of IFB-088
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: IFB-088 (2.5-60.0mg) oral capsuleDrug: Placebo (2.5-60.mg) oral capsuleDrug: IFB-088 (15.0-50.0mg) oral capsuleDrug: Placebo oral (15.0-50.0mg) capsule
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2022-01-26
- Lead Sponsor
- InFlectis BioScience
- Target Recruit Count
- 72
- Registration Number
- NCT03610334
- Locations
- 🇫🇷
Eurofins|Optimed, Gières, France
🇫🇷Centre d'Investigation Clinique - Centre de Pharmacologie Clinique et d'Evaluations Thérapeutiques (CIC-CPCET), Marseille, France
© Copyright 2025. All Rights Reserved by MedPath